Spinal Implants and Surgery Devices Market - Insights on Scope and Growing Demands 2025

According to the new market research report spinal implants and surgery devices market is projected to reach USD 13.8 billion by 2025 from USD 10.3 billion in 2019, at a CAGR of 5.0%.

Advancements in spine surgery technologies, increasing incidence of spinal disorders, the launch of advanced bone grafting products, and the increasing adoption of minimally invasive spine surgeries are driving the growth of the spinal implants and surgery devices market. However, the high cost of spinal surgery and uncertainties surrounding reimbursement are expected to restrain the growth of this market during the forecast period.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=712

Based on product, the spinal implants and surgery devices market is segmented into thoracic fusion and lumbar fusion devices, cervical fusion devices, spine biologics, non-fusion devices, vertebral compression fracture treatment devices, spinal decompression devices, and spine bone stimulators. The thoracic fusion and lumbar fusion devices segment accounted for the largest share of the spinal implants and surgical devices market. This can be attributed to the increasing preference for minimally invasive spine procedures; rising incidence and prevalence of spine degenerative diseases such as spondylolisthesis, degenerative scoliosis, and spinal stenosis; and technological innovations in minimally invasive interbody fusion devices.

Based on technology, the spinal implants and surgery devices market is segmented into spinal fusion and fixation, vertebral compression fracture treatment, motion preservation/non-fusion, and spinal decompression technologies. The spinal fusion and fixation technologies segment accounted for the largest share of the market in 2019. This can be attributed to the rising incidence of target diseases with the rising geriatric population across the globe, growing number of spinal fusion procedures, and technological advancements in spinal fusion techniques and bone grafting procedures.

Based on the type of surgery, the spinal implants and surgery devices market is segmented into open and minimally invasive surgeries. The open surgeries segment accounted for the largest share of the spinal implants and surgery devices market in 2019. The large share of this segment can be attributed to the increasing preference for open spine surgeries among medical professionals, rising incidence of spinal deformities, and technological advancements in spinal fusion surgeries.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=712

The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the improving healthcare infrastructure, rising awareness, improving reimbursement scenario, and the growing insurance coverage in several APAC countries.

Ambulatory EHR Market Insights on Scope and Growing Demands 2021

According to research the research report “Ambulatory EHR Market is expected to reach USD 5.20 billion by 2021 from USD 3.92 billion in 2016, at a CAGR of 5.8% in the next five years (2016 to 2021).

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides an overall understanding of the market. In this report, the market is segmented on the basis of application, delivery mode, practice size, end user, and region. On the basis of application, the market is segmented into practice management, patient management, e-prescribing, referral management, population health management, decision support, and health analytics. The practice management segment accounted for the largest share of the ambulatory EHR market in 2016.

Download Free Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=235617627

On the basis of delivery mode, the market is segmented into cloud-based solutions and on-premises solutions.
On the basis of practice size, the market is categorized into large practices, small-to-medium practices, and solo practices.
On the basis of end user, the market is divided into hospital-owned ambulatory centers and independent centers.
On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

Geographic analysis reveals North America accounted for the largest share of the market in 2016, owing to the federal mandates, increasing geriatric population, collaboration between stakeholders, the need to curtail healthcare costs, payment deductions driving the adoption of EHR, conferences and workshops to raise awareness in the U.S., growing efforts to enhance healthcare delivery, and the adoption of digital recordkeeping in Canada.

Some of the major players in the market include Cerner Corporation (U.S.), McKesson Corporation (U.S.), Allscripts Healthcare Solutions, Inc. (U.S.), Epic Systems Corporation (U.S.), eClinicalWorks (U.S.), athenahealth, Inc. (U.S.), NextGen Healthcare Information Systems, LLC (U.S.), Practice Fusion, Inc. (U.S.), eMDs, Inc. (U.S.), Amazing Charts, LLC (U.S.), GE Healthcare (U.S.), and Greenway Health, LLC (U.S.).

qPCR Reagents Market - New Growth Opportunities for Market Leaders

According to research report qPCR reagents market is poised to reach $1,893.9 Million by 2020 From USD 1,307.0 Million in 2015, growing at a CAGR of 7.7%, during 2015 to 2020.

Over the last decade, the qPCR industry has witnessed significant technological advancement & robust product development. These advancements are transforming the field of forensic & disease diagnostic application of qPCR; leading to more effective & timely treatment of chronic and infectious diseases (such as cancer, AIDS, influenza, and hepatitis).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102087588

North America and a major part of Europe are mature markets for qPCR reagents. However, emerging regions such as Asia-Pacific (including China and India) are expected to become new revenue-generating pockets in the market over the next five years. The North American qPCR reagents market is expected to hold the largest share during the forecast period owing to high penetration of qPCR technologies among key end users, increasing public & private funding to expand the application base of qPCR, ongoing product advancements in the field of qPCR reagents, and continuous reduction in the average cost of genome sequencing.

The Asia-Pacific region is expected to witness the fastest market growth for qPCR reagents during the forecast period. Growth in this market is fueled by increasing penetration of global life sciences companies in this region, rising focus of governments on increasing the awareness about gene-based disease diagnosis and treatment, growing public and private support to develop novel qPCR technologies, and advancing cancer research in Japan.

Due to the significant growth opportunities offered by emerging countries, a number of players operating in the market are focusing on expansion in these regions. For instance, in November, 2012, Thermo Fisher Scientific established a manufacturing facility in Suzhou (China) with an investment of USD 20 Million. The facility is involved in the manufacturing of life science equipment and consumables (including qPCR reagents) and caters to the life science & pharmaceutical industry. Similarly, in August, 2012, Bio-Rad Laboratories established the Digital Biology Center (U.S.) to develop innovative PCR products based on the company’s droplet partitioning technology.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=102087588

The qPCR reagents that are used for pathogen detection, forensic applications, and disease diagnosis offer a promising future to market aspirants focusing on expanding their revenue base in the market. Their growth is propelled by the increasing R&D to develop and commercialize novel products, growing market adoption of gene-based diagnostic techniques, and rising emphasis on effective & early disease diagnosis across major markets. Several companies such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and Takara Bio are investing in these high-growth markets to gain higher profits and to increase their shares in the global qPCR reagents market.

Coronary Stent Market | Growth, Trends, and Forecast 2021

According to the research report the coronary stent market is expected to reach USD 10.31 billion by 2021 from USD 7.16 billion in 2016, at a CAGR of 7.6% from 2016 to 2021. Major factors driving the growth of this market include technological advancements, increasing number of percutaneous coronary intervention (PCI) procedures, rising burden of CAD, increasing demand for minimally invasive procedures, and rising geriatric population.

Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=77411272

Major Market Developments:
• In November 2016, Abbott received approval from the Ministry Of Health, Labor And Welfare (MHLW) (Japan) for its Absorb bioresorbable heart stent. This is the only dissolving heart stent used for the treatment of patients with coronary artery disease in Japan. This approval will help the company expand its presence in the Japanese market.
• In January 2016, Abbott acquired St. Jude Medical, Inc. (U.S.), a manufacturer of products for heart failure, atrial fibrillation, and cardiac rhythm management for USD 25 billion. The acquisition helped Abbott to strengthen its coronary intervention product offerings and increase its presence in the cardiovascular devices market
• In May 2016, Boston Scientific collaborated with Mayo Clinic (U.S.) to share intellectual property and speed the development of medical devices. This collaboration focuses on the development of medical technologies in the fields of interventional cardiology, heart rhythm management, endoscopy, neuromodulation, urology and pelvic health. This will help the company to strengthen its product offerings.
The coronary stent market is segmented based on type, material; mode of delivery, end user, and region.

Based on type, the coronary stent market is segmented into bare-metal stents, drug-eluting stents and bioabsorbable stents. The bioabsorbable stents segment is expected to grow at the highest CAGR during the forecast period. These stents help restore normal vasomotion, improve abnormal endothelial function, and lower the risk of complications such as thrombosis and inflammation. Such advantages are driving high growth in the bioabsorbable stents market.

Based on mode of delivery, the coronary stents market is segmented into balloon-expandable stents and self-expanding stents. The balloon-expandable stents segment is expected to grow at the highest CAGR during the forecast period due to factors such as increasing research activities to improve this technology, high utilization of these stents, and growing regulatory approvals for balloon-expandable stents.

Asia is expected to grow at a highest CAGR during the forecast period. Factors such as large population base, growing prevalence of cardiac diseases, rising adoption of advanced technologies, and low manufacturing costs in the region are expected to drive market growth in Asia. Moreover, the growing focus of major players in this region is expected to boost the coronary stents market in Asia.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=77411272

Key players in the Coronary Stent Market include Medtronic plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), Biosensors International Group, Ltd. (Singapore), BIOTRONIK SE & Co. KG (Germany), B. Braun Melsungen AG (Germany), TERUMO CORPORATION (Japan), STENTYS SA (France), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), and Translumina GmbH (Germany).

Key players in this market are pursuing strategies such as product approvals; product launches and enhancements; partnerships, collaborations, and contracts; expansions; acquisitions; and certifications.

Gel Documentation Systems Market - Global Forecast to 2023

The Gel Documentation Systems Market is projected to grow from USD 258 million in 2018 to USD 304 million by 2023, at a CAGR of 3.3% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17162887

Growth in the gel imaging systems market is mainly driven by the increasing prevalence of infectious and chronic disease, and rising research & development expenditure in the pharmaceutical and biotechnology companies.

By product, the instruments segment is expected to grow at the highest rate during the forecast period in the gel documentation systems market

Based on product, the gel imaging systems market is segmented into three segments, namely, instruments, software, and accessories. The instruments segment is further divided into digital gel documentation instruments and gel documentation instruments. During the forecast period, the instruments segment is estimated to register the highest growth rate in the overall gel imaging systems market. This is mainly due to the increased R&D activities in the biotechnology and pharmaceutical industries.

Request for Reports Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=17162887

By end user, the academic and research institutes segment is expected to be the largest contributor to the gel documentation systems market in 2018

Based on end user, the gel imaging systems market is segmented into academic and research institutes; pharmaceutical & biotechnology companies; diagnostic laboratories. The academic and research institutes segment is estimated to account for the largest share of the overall market in 2018. This is primarily attributed to the increasing research activities on genomics and proteomics in research institutes and rising government funding in academic institutes.

Prosthetic Heart Valve Market | Industry Report 2017 - 2022

According to the new market research report Prosthetic Heart Valve Market is projected to reach USD 8.86 Billion by 2022 from USD 4.84 Billion in 2017, at a CAGR of 12.9% during the forecast period.
The key factors driving the growth of this market include the rising geriatric population and the subsequent growth in the prevalence of HVD, regulatory approvals for new and advanced prosthetic heart valves, increasing government funding for heart valve research, rising awareness about HVD, and favorable reimbursement scenario for prosthetic heart valves.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=245407958
Medtronic plc (Ireland), Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), LivaNova PLC (U.K.), Symetis SA (Switzerland), Jenavalve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK Healthcare Limited (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil) are the prominent players in the global prosthetic heart valves market.
The Transcatheter Heart Valves Segment Is Expected to Account for the Largest Share of the Prosthetic Heart Valves Market in 2017
Based on the type of valve, the prosthetic heart valves market is segmented into transcatheter heart valves, tissue heart valves, and mechanical heart valves. The transcatheter heart valves segment is expected to command the largest market share in 2017. The large share of this segment can be attributed to factors such as the rising prevalence of aortic stenosis, increasing pool of patients owing to approvals for extended valve indications, and technological advancements. The preference for transcatheter heart valves is expected to see high growth in the future as they are implanted through a minimally invasive procedure while the other valve types require open-heart surgery.
Request For Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=245407958
North America to Command the Largest Market Share in 2017
Based on region, the prosthetic heart valves market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. In 2017, North America is expected to account for the largest share of the global market. Factors such as the rapid growth in the aging population and prevalence of valvular heart diseases, favorable reimbursement scenario, and rising product approvals for heart valves are contributing to the growth of the North American prosthetic heart valves market are driving the growth of the North American prosthetic heart valves market.

Clinical Alarm Management Market Major Players and Global Forecast 2023

The global clinical alarm management market is expected to reach USD 1,724 million by 2023 from an estimated USD 457 million in 2018, at a CAGR of 30.4%. The clinical alarm management market is rapidly emerging with many regional as well as international companies. In 2017, Koninklijke Philips (Netherlands) and Vocera Communications (US), held a share of approximately 70.0% of the clinical alarm management market.
The major clinical alarm management vendors include Koninklijke Philips (Netherlands), Vocera Communications (US), Ascom Holdings (Switzerland), Spok, Inc. (US), Bernoulli Enterprise (US), Connexall (Canada), Mobile Heartbeat (US), GE Healthcare (US), Capsule Technologie (US), and Masimo Corporation (US). These players have adopted various growth strategies, such as product launches and enhancements; acquisitions; expansions; and agreements, partnerships, mergers, and collaborations. Product launches and partnerships and have been the most dominating strategy adopted by major players from 2015 to 2018, which helped them to innovate on their offerings and broaden their customer base.

Download PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=69939577
Koninklijke Philips dominated the global clinical alarm management market in 2017. The firm’s clinical alarm management solutions are designed to help caregivers manage alarms and reduce fatigue. Through these solutions the caregivers receive actionable notifications and communicate directly on a smartphone which enables workflow optimization, drives efficiency, and facilitates collaboration among staff. For instance, St. Antonius Hospital (the Netherlands) reduced irrelevant ICU alarms by 40% by utilizing Philips’ clinical alarm management solutions. The company focuses on inorganic growth strategies such as agreements, collaborations, and partnerships—to strengthen its presence in the clinical alarm management market. For instance, in November 2015, Philips entered into a partnership with Mackenzie Health (Canada) to enable Mackenzie Health to get early and ongoing access to Philips’ latest healthcare technology innovations, including systems interoperability, diagnostic imaging equipment utilization, radiology practice management, patient-centric design, and alarm management.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=69939577

Vocera Communications is one of the leading players in the clinical alarm management market. The firm has been in the market for about 18 years and offers a diversified range of solutions, including Vocera Alarm Management, Vocera Engage, and Vocera Collaboration Suite among others. Vocera strategically focuses on innovation, which is evident from its investments in R&D (USD 27.7 million (17.0% of sales) in 2017). The firm plans to further invest in R&D activities and improve its R&D capabilities to unlock additional synergies and growth opportunities. This helps the company to constantly develop innovative solutions such as Vocera Alarm Management and Vocera Engage.
Sales to the healthcare market accounted for 98.0%, 97.0% and 98.0% of its overall revenue for the years ended December 31, 2017, 2016, and 2015, respectively.

Sterility Testing Market –Top Key Players and Market Growth

According to the new market research report sterility testing market is expected to reach USD 941.0 Million by 2021 from USD 528.0 Million in 2016, at a CAGR of 12.3% from 2016 to 2021.
The growth of the sterility testing market can be attributed to the growth in the pharmaceutical and biotechnology industries, increase in the number of new drug launches, and increasing R&D in life science research.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=208866931

Major players in the sterility testing market include Merck KGaA (Germany), Charles River Laboratories International, Inc. (U.S.), bioMérieux SA (France), SGS S.A. (Switzerland), Sartorius AG (Germany), WuXi AppTec (China), Nelson Laboratories (U.S.), Danaher Corporation (U.S.), Pacific Biolabs (U.S.), Toxikon Corporation (U.S.), and Thermo Fisher Scientific, Inc. (U.S.).

Merck KGaA (Germany) dominated the sterility testing market in 2015. The company’s dominance in the market can be attributed to its robust product portfolio and strong geographic presence. The company focuses on organic as well as inorganic growth strategies for enhancing its market position. In September 2016, the company launched its Steritest Symbio Pump systems to enhance its product portfolio and increase its market presence. Furthermore, the company was focused on inorganic growth strategies. In November 2015, Merck KGaA acquired Sigma-Aldrich Corporation (U.S.); this acquisition helped the company strengthen its sterility testing product portfolio.

Charles River Laboratories International, Inc. (U.S.) held the second position in the sterility testing market in 2015. This can be attributed to the company’s strong sterility testing portfolio. The company adopted organic growth strategies such as mergers and acquisitions to boost its market share. In November 2015, Charles River acquired Celsis International Ltd. (U.S.). This acquisition helped the company to strengthen its microbial detection product portfolio. Also in November 2015, Charles River Laboratories acquired Oncotest GmbH (Germany), a global CRO dedicated to discovery services for oncology. This acquisition strengthened Charles River's portfolio of target discovery & validation services and in vivo pharmacology.

bioMérieux SA (France) held the third position in the sterility testing market in 2015. The company focuses on organic as well as inorganic growth strategies such as expansions and collaborations to enhance its market share. In March 2016, it entered into a distribution and co-development strategic partnership with Copan Italia S.p.A. (Italy). According to the terms of this agreement, bioMérieux SA and Copon will work together to distribute and develop solutions for microbiology laboratory automation and efficiency. Furthermore, the company was focused on organic growth strategies. In Octamer 2014, bioMérieux opened a new diagnostic testing facility in Isère, France. This facility enabled the company to develop new diagnostic solutions related to microbiology.

SGS S.A. (Switzerland) held the fourth position in the sterility testing market in 2015. The company adopted organic growth strategies such as expansions to boost its market share. In September 2016, SGS opened a new facility in Wiesbaden, Germany. The 500-m2 facility will provide extractables and leachables (E&L) testing to the pharmaceutical and related industries. This helped company to expand its quality control release testing capabilities at that facility. Also in December 2016, SGS acquired Quality Compliance Laboratories Inc. (U.S.). This acquisition helped the company to provide microbiological and analytical testing to pharmaceutical, nutraceutical, and cosmeceutical industries.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208866931

Based on the analysis of strategic developments undertaken by market players between 2013 and 2016, the key strategies followed by most companies in the sterility testing market are expansions and acquisitions. Some of the leading players that adopted this strategy include bioMérieux SA (France), Merck KGaA (Germany), Nelson Laboratories (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Charles River Laboratories (U.S.), and WuXi AppTec (China).

Liquid Biopsy Market is projected to reach $2,047.9 Million By 2022

The global liquid biopsy market is projected to reach USD 2,047.9 million by 2022 from USD 715.7 million in 2017, at a CAGR of 23.4%. The liquid biopsy market is a consolidated market with a large number of companies offering liquid biopsy instruments and accessories. In 2016, QIAGEN N.V. (Netherlands), Roche Diagnostics (US), and Illumina, Inc. (US) dominated the liquid biopsy market.
QIAGEN is the leading player in the liquid biopsy market in 2016. The company is a global provider of sample-to-insight solutions that aids in the transformation of biological samples into molecular insights. The company operates through its two business segments, namely, instruments and consumables & related products. QIAGEN provides solutions to more than 500,000 customers globally, in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharma and biotech companies), and academia (life sciences research). The company operates in the liquid biopsy market through its molecular diagnostics and life science tools customer base segment.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350

Roche Diagnostics ranked second in the liquid biopsy market in 2016. Roche Diagnostics focuses on the discovery, manufacturing, and marketing of medical devices used to screen, diagnose, and monitor therapies. The company operates in the liquid biopsy market through its molecular diagnostics segment. The company geographically operates in Europe, the Middle East and Africa, North America, Asia Pacific, and Latin America.

Illumina ranked third in the liquid biopsy market in 2016. The company provides sequencing and array-based solutions for genetic analysis. The company develops, manufactures, and markets integrated systems and life science tools for the analysis of genetic variation and biological function.
The company operates in the liquid biopsy market through its spinoff company “GRAIL Inc.”
Some of the other players competing in this market are Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), Pathway Genomics Corporation (US), ANGLE plc (UK), Vortex Biosciences (US), Epic Sciences (US), Cynvenio Biosystems Inc. (US), Personal Genome Diagnostics, Inc. (US), MedGenome Inc. (US), Exosome Diagnostics (US), NeoGenomics, Inc. (US), Foundation Medicine, Inc. (US), Sequenom, Inc. (US) MDxHealth SA (US), and Chronix Biomedical (US).

Get report sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350

Clinical Microbiology Market Size, Share, Trends and Forecast 2023

According to research report the clinical microbiology market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018 growing at a CAGR of 6.4% during forecast period. The technological advancements in the disease diagnostics, rising incidence of infectious diseases and growing outbreak of epidemics, and increased funding and public-private investments in the field of disease diagnosis are the key factors driving the growth of the clinical microbiology market during the forecast period.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=219135367

Strategic analysis of the market developments between 2014 and 2018 revealed that growth strategies such as product launches and enhancements; acquisitions; agreements, partnerships, collaboration; and expansions were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the clinical microbiology market. Among these business strategies, product launches & enhancements and partnerships & collaborations were the two most widely adopted growth strategies.

bioMérieux S.A. (France) held the leading position in the global clinical microbiology market in 2017. The company has a robust product portfolio and a strong geographical presence in more than 150 countries across the world. To maintain its leadership position in the market, the company has been focusing on R&D activities and product launches. In 2017, the company invested ~13% of its revenue in R&D activities, with the aim to improve product quality, accuracy, and reduce the overall throughput time required for a test. The company launched several products in the clinical testing space in the past four years, such as VITEK MS, FilmArray 2.0, VIDAS C. difficile GDH assay kit, GENE-UP diagnostic solution, ChromID Salmonella ELITE, and FilmArray Ebola test, among others. It also aims to increase its geographical presence and strengthen its product portfolio through growth strategies such as partnerships, collaborations, and expansions. In line with this, in 2017, the company established a new R&D center in France, which is a new multidisciplinary R&D center for infectious disease diagnostics. Further, in 2015, the company entered into a distribution agreement with COPAN (Italy), which helped the company to expand its product portfolio.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367

Danaher Corporation (US) held the second position in the global clinical microbiology market in 2017. The company operates in the clinical microbiology testing market through its wholly owned subsidiaries— Beckman Coulter and Cepheid. Danaher is focusing on strengthening its position in the global clinical microbiology market mainly by adopting strategies such as acquisitions and new product launches. The acquisition of Beckman Coulter Inc. (a major player in the US life sciences and diagnostics market) in June 2011 helped the company strengthen its product portfolio and increase its share in the clinical microbiology testing market.

The acquisition of Cepheid in November 2016 further helped to enhance the company’s position, expand its molecular diagnostic products portfolio, and increase its market share in the clinical microbiology testing market. The company also acquired Siemens Healthcare’s clinical microbiology business (July 2014) and Xitogen Technologies Inc. (April 2014) to strengthen its product offerings and geographic presence. The company launched several innovative products, such as DxM 6100 Autoplak Advanced System, Xpert Xpress Flu Test Kit, DxONE Clinical Information Management Tools, VERIS Human CMV Assay, and UniCel DxH Connected Workcell Solution, among others. These products have helped the company remain competitive in the microbiology testing market.

Single-use Bioreactors Market Development | Industry Report 2022

According to the new market research report Single-use Bioreactors Market is expected to grow at a CAGR of 21.9% from 2017 to 2022, to reach 2,685.1 Million by 2022 from USD 997.6 Million in 2017. In the current market scenario, there is a growing demand for single-use bioreactor products. The major factors driving the growth of the Single Use Bioreactors include the increasing adoption of SUBs among small companies and startups, reduced automation complexity, ease in cultivating marine organisms, and reduced impact on the environment.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49113750

The single-use bioreactors market is segmented based on product type, cell type, technology, application, end user, and region.

Based on product type, the market is segmented into monoclonal antibodies, vaccines, gene-modified cells, recombinant proteins, stem cells, and other products (growth factors, interferons, and antisense DNA & RNA). Among the above-mentioned product segments, the stem cells segment is estimated to witness the highest growth during the forecast period. The high growth in this segment can be attributed to advantages such as reduced medium consumption, ease of use, and the ability to monitor process parameters and cell health.

Research & Development is expected to be the Fastest-growing Application Segment in the Single-use Bioreactors Market

Thermo Fisher Scientific, Inc (U.S.) Held the Leadership Position in the SUB in 2014 Owing to Its Broad Product Portfolio and Strong Brand Name

Thermo Fisher Scientific, Inc. will hold the leadership position in the Single Use Bioreactors Market in 2014. The company has an extensive product portfolio, including bioreactors such as open architecture bioreactor systems, turnkey bioreactor systems, and bioreactor accessories. The company has a good reputation and a strong customer base for its SUBs. Sartorius AG holds the second-largest share. It is a leading provider of laboratory equipment and process technologies and has a vast product portfolio that has helped it to maintain its position in the Single Use Bioreactors Market.

The Single Use Bioreactors Market is highly consolidated, with the top five players accounting for a share of more than 75%. The major players include Thermo Fischer Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), GE Healthcare (U.S.), and Pall Corporation (U.S.).

Collaboration is the most preferred strategy adopted by key players in this market. Players adopted this strategy to enhance their product offerings, increase their market share, cater to the customers’ demands, and consolidate their market presence.
The wave-induced motion SUBs and stirred SUBs product segments of this market have emerged as revenue-generating pockets in countries such as the U.S., India, and China.

Get Sample Pages: https://www.marketsandmarkets.com/requestsample.asp?id=49113750

The Europe is expected to account for the largest share of the single-use bioreactors market in 2016. Government support for new biologics has encouraged the research and development of biologics. North America is accounted for the second-largest share of the single-use bioreactors market.
The key players in the single-use bioreactors market are Sartorius Stedim Biotech (France), Merck Millipore (Germany), GE Healthcare (US), Danaher (US), and Thermo Fisher Scientific (US).

Antimicrobial Susceptibility Testing Market worth 3.47 Billion USD by 2022

The global Antimicrobial Susceptibility Testing Market is expected to reach USD 3.47 Billion by 2022 from USD 2.71 Billion in 2017, at a CAGR of 5.1%. The major factors driving the growth of the antimicrobial susceptibility testing (AST) market include the rising prevalence of infectious diseases; increased funding, research grants, and public-private investments; and technological advancements towards rapid susceptibility testing methods.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206359984

By end user, the market is segmented into diagnostic laboratories and hospitals; pharmaceutical and biotechnology companies; contract research organizations; and research and academic institutes. The hospitals and diagnostic laboratories segment are expected to account for the largest share of the AST market in 2017 due to the increasing prevalence of infectious diseases, rising healthcare expenditure, and increasing number initiatives dedicated towards better antibiotic use. The AST market is segmented based on product into automated laboratory instruments, manual antimicrobial susceptibility testing products, culture and growth media, and consumables. The manual antimicrobial susceptibility testing products segment is expected to command the largest share of the global AST market in 2017. The large share of this segment is attributed to the benefits these products offer such as low cost, ease of use, reduced labour cost, and the compatibility of manual susceptibility testing products with a wide range of organisms. Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the global AST market during the forecast period (2017-2022). Factors such as the presence of prominent AST players in the region, increasing initiatives towards creating awareness about microbial resistance, and increasing healthcare expenditure are fuelling the growth of antimicrobial susceptibility testing market in this region.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=206359984

The major players operating in the antimicrobial susceptibility testing market include bioMérieux (France), Danaher (US), BD (US), Thermo Fisher (US), and Bio-Rad (US), among others.

qPCR Reagents Market Development | Industry Report 2020

According to research report qPCR reagents market is poised to reach $1,893.9 Million by 2020 From USD 1,307.0 Million in 2015, growing at a CAGR of 7.7%, during 2015 to 2020.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102087588

The qPCR reagents that are used for pathogen detection, forensic applications, and disease diagnosis offer a promising future to market aspirants focusing on expanding their revenue base in the market. Their growth is propelled by the increasing R&D to develop and commercialize novel products, growing market adoption of gene-based diagnostic techniques, and rising emphasis on effective & early disease diagnosis across major markets. Several companies such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and Takara Bio are investing in these high-growth markets to gain higher profits and to increase their shares in the global qPCR reagents market.

Thermo Fisher Scientific Inc. (U.S.) held the leadership position in the global qPCR reagents market, with a share of ~40%,. The company has a broad product portfolio for qPCR reagents, including master mixes, enzymes, nucleotides, primers, reagents, as well as consumables, among others. The company has a strong geographic presence in more than 50 countries across the globe, with key markets being the U.S., China, Germany, and the U.K. The company focuses mainly on the development of technologically advanced qPCR instruments and supporting reagents that can be used for multiple applications. In line with this strategy, Thermo Fisher Scientific has launched several qPCR reagents in the last three years, including SYBR Green master mixes and Taqman qPCR kits, among others.

North America (particularly the U.S.) is expected to hold the largest share of qPCR reagents market during the forecast period. Factors such as high penetration of qPCR technologies among key end users, increasing public & private funding to expand the application base of qPCR, ongoing product advancements in the field of qPCR reagents, and continuous reduction in the average cost of genome sequencing are driving the growth of the North American market.

On the basis of packaging type, the qPCR reagents market is classified into two major segments core kits and mastermixes. The qPCR core kits segment is expected to account for the largest share of the global market.

On the basis of end user, the market is classified into five segments hospitals and diagnostic centers, research laboratories and academic institutes, pharmaceutical and biotechnology companies, clinical research organizations, and forensic laboratories. The hospitals and diagnostic centers segment is expected to account for the largest market share of qPCR reagents market.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=102087588

Product development & commercialization, agreements, collaborations, and partnerships are the key strategies adopted by major players to strengthen their positions in the global qPCR reagents market.

Blood Gas Analyzer Market - key growth strategy adopted by major players

A number of factors, such as the growing number of patients being treated in ICUs, NICUs, and emergency departments, and the increasing adoption of technologically advanced biosensors and data analysis software for developing next-generation blood gas analyzers are expected to drive the growth of this market in the coming years.

According to the new market research Blood Gas Analyzer Market is expected to reach USD 636.0 Million by 2021, at a CAGR of 4.6% during the forecast period of 2016 to 2021.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=242278963

Players in the blood gas analyzers market adopted organic (new product launch) as well as inorganic growth strategies (acquisitions and agreements) to increase their market shares. New product launch was the most prominent growth strategy adopted by market players between 2013 and 2016; it accounted for a share of 23.5% of the total number of strategic developments undertaken by market players in this period.

Companies such as Roche Diagnostics Limited, Nova Biomedical, Abbott Laboratories, and OPTI Medical Systems, Inc. adopted the strategy of new product launch to develop novel blood gas analyzers, strengthen their product portfolios, and address the demands of their customers. In June 2016, Roche Diagnostics launched its blood gas learning application, namely, Blood Gas Learn Your ABGs. The new app helps in learning and interpreting arterial blood gases. This enabled the company to enhance its market visibility. Similarly, Nova launched Stat Profile Prime, a blood gas analyzer, in May 2014. This testing system can be combined with Nova’s zero maintenance cartridge technology, which gives faster and accurate results. The launch of this product helped the company to expand its product offerings in the point-of-care testing market.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=242278963

Several players also focused on the strategy of acquisitions to strengthen their market positions and enhance their R&D capabilities. In February 2016, Abbott entered into an agreement with Alere Inc. (a Massachusetts-based leading point-of-care diagnostics company), to acquire it for USD 5.8 billion. With this agreement, Abbott is expected to become one of the leaders in the blood gas analyzers market. ERBA-Transasia Group (India) acquired Lumora, a U.K.-based provider of patented molecular diagnostic products for the clinical and industrial markets, in September 2015. This helped the ERBA-Transasia Group to expand its product portfolio and strengthen its overall market presence.

Sterility Testing Market – Opportunities, Challenges | Global Forecast 2021

According to the new market research report sterility testing market is expected to reach USD 941.0 Million by 2021 from USD 528.0 Million in 2016, at a CAGR of 12.3% from 2016 to 2021.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208866931

Market Dynamics:
Drivers
• Growth of pharmaceutical & biotechnology companies
• Increasing number of drug launches
• Government support for pharmaceutical and biotechnology industries
• Increasing R&D investment in life sciences
Restraints
• High degree of consolidation, major barrier for new market entrants
• Stringent regulatory frameworks and time-consuming approval processes
Opportunities
• Emerging markets
• Increasingly pharmaceutical outsourcing
Challenges
• Shortage of skilled professionals

Growth in the pharmaceutical and biotechnology industries, increase in the number of new drug launches, and increasing R&D in life science research are the key factors driving the growth of this market. The market is further driven by factors such as increasing government support for pharmaceutical and biotechnology industries.

This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, and strategies impacting the sterility testing market, along with revenue estimates & forecasts and market share analysis.

Pharmaceutical and biological manufacturing
With stringent regulatory controls in place, process monitoring, and quality control are carried out for the entire production chain of pharmaceutical and biopharmaceutical products. In this process, sterility testing is carried out for raw materials, bulk lot release testing, and final product release testing.

Medical Device manufacturing
In the medical device industry, the product sterility test is necessary for ensuring that medical devices are free from viable microorganisms. Some of the important medical devices tested for sterility tests include catheters, needles, orthopedic implants, contact lenses, anesthetic and respiratory equipment, and dental implants.

Get Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=208866931

The major players in the sterility testing market include Merck KGaA (Germany), Charles River Laboratories International, Inc. (U.S.), bioMérieux SA (France), SGS S.A. (Switzerland), Sartorius AG (Germany), WuXi AppTec (China), and Thermo Fisher Scientific, Inc. (U.S.). These players are increasingly undertaking mergers and acquisitions, and product launches to develop and introduce new technologies and products in the market.

Pacemakers Market | Top Players & Business Intelligence 2023

According to research report the pacemakers market is projected to reach USD 4.9 billion by 2023 from USD 4.4 billion in 2018, at a CAGR of 2.0% during the forecast period. A pacemaker is a medical device used when the heart is unable to produce electrical impulses naturally. When the heart’s natural pacemaker is defective or when the electrical pathways of the heart are blocked, it can cause irregular heartbeats, as known as arrhythmias. A pacemaker uses electrical pulses to prompt the heart to beat at a normal rate to treat arrhythmias.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=243344814

• The implanted pacemakers segment, by implantability, is projected to grow at the higher CAGR during the forecast period. These devices are often placed in the chest area, just under the collarbone, to send electrical signals to start or regulate the patient’s heartbeat

• The dual-chamber pacemakers segment, by technology, is projected to grow at the highest CAGR during the forecast period. A dual-chamber pacemaker has two leads and can be external or implantable. It connects to both chambers on the right side of the heart—the right atrium and the right ventricles—and can coordinate functions between the atria and ventricles.

• The MRI compatible pacemakers segment, by type, is projected to grow at the highest CAGR during the forecast period. The development of MRI Compatible pacemakers is a major advancement in the pacemakers market. It is estimated that 75% of patients who currently have an implantable cardiac pacemaker will need MRI scans during their lifetimes.

• The hospitals & cardiac centres segment, by end user, is projected to grow at the highest CAGR during the forecast period. Factors such as the large number of cardiovascular surgical procedures performed in hospitals, improving healthcare infrastructure, and favourable reimbursement scenario are driving the growth of the pacemakers market for hospitals & cardiac centres.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=243344814

The major pacemaker’s vendors include Medtronic (Ireland), Abbott (US), and Boston Scientific (US) BIOTRONIK (Germany), LivaNova (UK), OSCOR (US), Pacetronix (India), MEDICO (Italy), Osypka Medical (Germany), and Lepu Medical (China). These players have adopted various growth strategies such as expansions, acquisitions, and new product launches to expand their presence in the global pacemakers market. Product launches has been the most dominating strategy adopted by major players from 2015 to 2018. This has helped them to expand their consumer base and address the unmet needs of end users.

Surgical Drains Market Development | Global Forecast 2022

According to research report the surgical drains market is expected to reach USD 2.18 Billion by 2022 from USD 1.82 Billion in 2017, growing at a CAGR of 3.7%. The growth of this market is mainly driven by the growing geriatric population, increasing number of surgical procedures, and rising awareness programs globally.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206173813

• Based on product, the market is segmented into accessories and surgical drainage systems. The surgical drainage systems segment is expected grow at the highest CAGR during the forecast period. The high growth in this segment is attributed to the growing volume of high-risk surgical procedures and the benefits associated with surgical drainage systems, such as accurate measurement of drainage, lowering bacterial levels, and effective in closing wound edges.
• Based on type, the surgical drains market is segmented into active drains and passive drains. The active drains segment is expected to register the highest CAGR during the forecast period. Advantages offered by active drains, such as efficient fluid removal and prevention from bacterial infection are supporting the growth of this market.
• Based on application, the surgical drains market is segmented into general surgery, cardiac and thoracic surgery, orthopedic surgery, obstetrics/gynecology surgery, and other surgeries. The cardiac and thoracic surgery segment is expected to register the highest CAGR during the forecast period. The high growth of this market is attributed to the large number of thoracic & cardiovascular surgeries performed across the globe owing to the high prevalence of cardiovascular diseases (CVDs).

Among the four regional segments covered in the surgical drains market—North America, Europe, Asia, and the Rest of the World (RoW), Asia is expected to grow at the highest CAGR during the forecast period. The high demand for advanced wound care and surgical care products in several Asian countries, rising geriatric population, increasing number of surgical procedures, rising prevalence of chronic as well as diabetic wounds, and focus of major players on enhancing their presence in this region are some of the key factors driving the growth of the surgical drains market in Asia.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=206173813

Some of the top companies in this market include Medtronic (Ireland), B. Braun (Germany), Cardinal Health (US), Stryker (US), and Cook Medical (US).

The surgical drains market is highly competitive with several big and small players. Prominent players in this market include B. Braun (Germany), Cardinal Health (US), ConvaTec (UK), C.R. Bard (US), Redax (Italy), Ethicon (US), Stryker (US), Romsons (India), Medtronic (Ireland), Medline Industries (US), Cook Medical (US), Poly Medicure (India), Zimmer Biomet (Indiana), Global Medikit (India), Degania Silicone (Israel), Aspen Surgical (US), National Surgical (Australia), Axiom Medical (US), Péters Surgical (France), Ningbo Luke medical China), Goharshafa (Iran), ARMSTRONG MEDICAL (UK), Angiplast (India), CHIMED (Italy), and pfm medical (Germany).

Coagulation Analyzers Market Top Key Players and Global Forecast 2021

According to research report the coagulation analyzers market is projected to reach USD 4.84 billion by 2021 from USD 2.98 billion in 2016, at a CAGR of 10.2% from 2016 to 2021.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197226392

• Siemens AG was the largest player in the global coagulation analyzers market, with a share of 24.7% in 2015. The company has a strong presence in the U.S. and in regions such as Europe and Asia-Pacific. It focuses on product launches and agreements as its key growth strategies.
• Thermo Fisher Scientific, Inc. (U.S.) was the second-largest player in the coagulation analyzers market. The company operates in over 50 countries across North America, Europe, Asia, and Latin America. The company pursues the strategies of agreements and expansions in order to increase its share in the coagulation analyzers market.
• Roche Diagnostics (Switzerland) held the third position in the global coagulation analyzers market. The company focuses on introducing innovative and technologically advanced products in the market.

The coagulation analyzers market is consolidated in nature due to the presence of a few large players. The prominent players in the coagulation analyzers market include are Siemens AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Sysmex Corporation (Japan), Nihon Kohden Corporation (Japan), Diagnostica Stago (France), Helena Laboratories (U.S.), Instrumentation Laboratory (U.S.), and International Technidyne Corporation (U.S.).

Coagulation Analyzers Market Dynamics:
Drivers
• Increasing Prevalence of Cardiovascular Diseases and Blood Disorders
• Rising Aging Population
• Development of High-Sensitivity POC Coagulation Testing
• Increasing Laboratory Automation
Restraint
• High Cost of Fully Automated Coagulation Analyzer
Opportunities
• Emerging Markets
Challenges
• Slow Adoption of Advanced Hemostasis Instruments in Emerging Economies

This market is segmented based on product, test, technology, end-users, and regions. The coagulation analyzers market consists of various products that are used by clinical laboratories, hospitals, patient self-testing and others. Based on product, coagulation analyzers market is segmented into clinical laboratory analyzers and PoC testing analyzers. The clinical laboratory analyzers segment is expected to account for the largest share of the global coagulation analyzers market in 2016. Owing to increasing rental agreements, the consumables market is expected to grow in the coming years.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=197226392

Veterinary Endoscopy Market Recent Development | Industry Report 2023

According to research report the Veterinary Endoscopy Market is expected to reach USD 219.0 million by 2023 from USD 159.8 million in 2018, at a CAGR of 6.5%. The increasing number of pet insurance, growing pet population, rising number of veterinary practitioners and advanced applications of veterinary endoscopes are some of the major factors driving the growth of this market.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42907480

By animal type, the market is categorized into companion animals, large animals, and other animals. The companion animals’ segment is expected to grow at the fastest rate during the forecast period. The rising pet healthcare expenditure and the growing companion animal population are the key factors driving the growth of this segment.

Based on end users, the veterinary endoscopy market is classified into hospitals and academic institutes and clinics. The hospitals and academic institutes segment is estimated to grow at the fastest rate during the forecast period. Increasing number of endoscopy procedures which are performed in veterinary hospitals is driving the growth of this segment.

Based on product type, the market is categorized into flexible endoscopes, rigid endoscopes and other endoscopes. The flexible endoscopes segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can primarily be attributed to the wider applications of flexible endoscopes compared to rigid endoscopes.

By procedure, the market is categorized into flexible endoscopy, rigid endoscopy, and other procedures. The flexible endoscopy segment is expected to grow at the highest rate during the forecast period. Increasing number of flexible endoscopy procedures is the key factor contributing to the high growth rate of this segment.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=42907480

North America is expected to lead the market in 2018

Based on region, the veterinary endoscopy market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to dominate the market in 2018. The large share can be attributed to the rising adoption of companion animals, increasing pet healthcare insurance, and improved veterinary healthcare infrastructure.

Clinical Alarm Management Market Development | Industry Report 2023

According to research report the clinical alarm management market is expected to reach USD 1,724 million by 2023 from an estimated USD 457 million in 2018, at a CAGR of 30.4% during the forecast period. Growth in the clinical alarm management market can be attributed to the increasing alarm fatigue, high prevalence of chronic diseases, growth in the geriatric population, need for cost-containment in healthcare delivery, and rising prominence and usage of big data and mHealth tools. However, the lack of interoperability in HCIT solutions and the high investments needed to build an effective infrastructure for HCIT capabilities among end users may hamper the adoption of clinical alarm management solutions and services during the forecast period to a certain extent.

Download PDF Brchure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=69939577

The clinical alarm management market is segmented based on component, product, end user, and region.

• Based on component, the global clinical alarm management market is segmented into two broad categories based on component, namely— solutions and services. The services segment is expected to grow at the highest CAGR during the forecast period owing to the increasing adoption of clinical alarm management solutions and indispensable and recurring nature of services.
• Based on product, the global clinical alarm management market is categorized into nurse call systems, physiological monitors, EMR integration systems, bed alarms, ventilators, and others (infusion pumps and pulse oximeters). The EMR integration systems segment is also expected to grow at the highest rate during the forecast period owing to the increased adoption of EHRs and other interoperability solutions in healthcare organizations, growing regulatory requirements & healthcare reforms, shift of point-of-care diagnostics from hospitals to home care settings, and the need for integrated healthcare systems to improve the quality and outcome of healthcare systems.
• Based on end user, the global clinical alarm management market is segmented into hospitals, long-term care centres, and ambulatory care centres & home care settings. The ambulatory care centres & home care settings segment is expected to register the highest CAGR during the forecast period. The high growth in this segment can be attributed to the rising need to streamline administrative tasks, secure clinical information, and improve access to information; increasing need for early detection and intervention for reducing the risk of acute complications; and increasing focus on reducing treatment costs; and benefits of clinical alarm management in remote patient monitoring.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=69939577

Geographically, North America is expected to dominate the global clinical alarm management market in 2018. The clinical alarm management market in the region is driven by the increasing cases of alarm fatigue and initiatives by government bodies to curtail the effects of alarm fatigue and the increasing need for integrated healthcare IT systems to ensure reliability, efficient maintenance of data, data integrity, and timely availability of patient data to authorized healthcare professionals.

Sternal Closure Systems Market Development | Industry Report 2023

According to the new market research report Sternal Closure Systems Market is estimated to be valued at USD 2.02 billion in 2018 and is projected to reach USD 2.61 billion by 2023, at a CAGR of 5.2%. The increased target patient population coupled with the subsequent increase in the number of surgical procedures, growing availability of medical reimbursements across major markets, and technological advancements in sternotomy techniques are expected to drive the demand for sternal closure systems during the study period.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152164684

In the last decade, the sternal closure systems market has witnessed several mergers and acquisitions. For instance, Vance Street Capital LLC and A&E Medical Corporation (US) acquired Medical Concepts (Netherlands), with the aim to increase their product portfolio of single-use medical products in 2016. In this report, the market has been segmented by product, procedure, material, and region.

On the basis of product, the market is segmented into closure devices and bone cement. Closure devices accounted for the largest share of the sternal closure systems market in 2017. The large share of this segment can be attributed to the ongoing technological advancements in closure devices, increasing number of complex cardiovascular surgeries, and growing availability of medical reimbursements across the developed markets.

Based on procedure, the market is segmented into median sternotomy, hemisternotomy, and bilateral thoracosternotomy. The median sternotomy segment is expected to be the fastest-growing segment of the market during the forecast period. Median sternotomy is a widely used surgical procedure for accessing the body cavity via sternal bone during cardiothoracic, spinal, and pulmonary surgeries. Rising number of critical patients suffering from cardiovascular diseases, significant availability of reimbursement for critical cardiac surgeries across developed markets, and rising awareness among surgeons about the clinical benefits offered by technologically advanced sternal closure products during target cardiovascular surgeries are expected to drive the growth of the median sternotomy segment during the forecast period.

By material, the sternal closure systems market for medical devices is segmented into stainless steel, PEEK, and titanium. The titanium material segment is expected to grow at the highest CAGR in the sternal closure systems market. Increased market focus on titanium products due to the associated advantages and economies-of-scale, growing number of clinical research studies to evaluate the clinical efficacy of these products during sternal closure, and increased commercialization of titanium-based sternal closure systems across developed countries (especially in the US) are some the factors driving the growth of this segment.

Based on region, the sternal closure systems market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). Asia Pacific is projected to be the fastest-growing regional segment in the sternal closure systems market during the forecast period. Rapid growth in the healthcare expenditure in emerging APAC countries (such as China and India), growing adoption of advanced sternum closure techniques among cardiothoracic surgeons, large patient population for target diseases, the rapidly growing geriatric and obese population (especially in Japan, India, and China), increasingly localized device manufacturing as well as strengthening of distribution networks of prominent manufacturers, and growing trend of medical tourism across APAC countries are expected to drive the growth of the sternal closure systems market in APAC during the forecast period.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152164684

In addition, emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for market players owing to the rising focus of local governments to improve healthcare infrastructure of countries and presence of a large patient pool.

RSV Diagnostics Market Development | Industry Report 2022

According to the new market research report RSV Diagnostics Market is expected to reach USD 929.2 Million by 2022 from USD 574.3 Million in 2017, at a CAGR of 10.1%. RSV diagnostics is done to diagnose lower respiratory tract infections (LRTIs) in children caused by respiratory syncytial virus (RSV) which is the leading cause of infant hospital admissions in developed countries. Factors driving the growth of this market include the rising burden of RSV infections, growing demand for PoC molecular diagnostic tests for the diagnosis of RSV infections, and increasing approval of RSV diagnostic kits and assays.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=95683942

The RSV diagnostics market is consolidated in nature due to the presence of a large number of players. The key players in the market are bioMerieux (France), Becton Dickinson (US), Abbott (US), Roche (Switzerland), Danaher (US), Thermo Fisher (US), Luminex (US), BioCartis (Belgium), Hologic (US), and Fast Track Diagnostics (Luxembourg).

Most companies in the RSV diagnostics market adopted agreements, expansions, and product launches as the key business growth strategy. These strategies accounted for the largest share of the overall growth strategies mapped from 2014 to 2017. Some of the leading players who adopted these strategies include bioMerieux (France), Abbott (US), Roche (Switzerland). bioMérieux is a world leader in in vitro diagnostics, molecular diagnostics, and microbiology automation. The company operates through two major business divisions, namely, clinical diagnostics and industrial microbiology.

• On the basis of products, the RSV diagnosis market is categorized into kits and assays, instruments, and other products. The kits and assays segment is expected to register the highest growth during the forecast period. Growth in this market is mainly due to the increasing approval of RSV diagnostic kits and assays.
• Based on method, the market is segmented into molecular diagnostics, rapid antigen detection tests, and other methods. The molecular diagnostics segment is estimated to register the highest growth during the forecast period. Growth in this segment can be attributed to the growing demand for molecular diagnostic tests for the diagnosis of RSV infections.
• Based on end user, the market is segmented into hospitals & clinics and home care. The hospitals and clinics segment is estimated to grow at the highest rate during the forecast period. The increasing demand for RSV diagnostic testing in hospitals and clinics is driving the growth of this segment.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=95683942

North America is estimated to command the largest share of the market during the forecast period.

Based on region, the RSV diagnostics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is estimated to dominate the RSV diagnostics market in 2017. This is mainly due to factors such as the increasing patient base of RSV diseases, technological advancements in PoC molecular diagnostic devices, and growing healthcare expenditures.

Veterinary Endoscopy Market Development | Industry Report 2023

According to research report the Veterinary Endoscopy Market is expected to reach USD 219.0 million by 2023 from USD 159.8 million in 2018, at a CAGR of 6.5%. Some of the factors driving the growth of this market include increasing use of endoscopes in the diagnosis of animal gastrointestinal diseases, growing population of companion animals and advanced applications of veterinary endoscopy procedures. Increasing pet insurance and growing animal health expenditure; and rising number of veterinary practitioners are some other factors supporting the growth of the market.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42907480

Based on product type, the market is categorized into flexible endoscopes, rigid endoscopes and other endoscopes. The flexible endoscopes segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can primarily be attributed to the wider applications of flexible endoscopes compared to rigid endoscopes.

By procedure, the market is categorized into flexible endoscopy, rigid endoscopy, and other procedures. The flexible endoscopy segment is expected to grow at the highest rate during the forecast period. Increasing number of flexible endoscopy procedures is the key factor contributing to the high growth rate of this segment.
By animal type, the market is categorized into companion animals, large animals, and other animals. The companion animals’ segment is expected to grow at the fastest rate during the forecast period. The rising pet healthcare expenditure and the growing companion animal population are the key factors driving the growth of this segment.

Based on end users, the veterinary endoscopy market is classified into hospitals and academic institutes and clinics. The hospitals and academic institutes segment is estimated to grow at the fastest rate during the forecast period. Increasing number of endoscopy procedures which are performed in veterinary hospitals is driving the growth of this segment.

Based on region, the veterinary endoscopy market is segmented into North America, Europe, Asia Pacific and the Rest of the World (RoW). The veterinary endoscopy market in the Asia Pacific region is expected to register the highest CAGR during the forecast period. Growth in this region can be attributed to the rising pet ownership, increasing animal health expenditure, and rapid development in the animal healthcare infrastructure in the developing countries such as India and China.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=42907480

Given the immense opportunities in major applications of veterinary endoscopy, market leaders and emerging players are increasingly focusing on the market in the segments mentioned above to increase their revenues and are also looking to expand their reach to emerging economies.

Surgical Drains Market Top Players and Growth Strategies | Global Forecast 2022

According to research report the surgical drains market is expected to reach USD 2.18 Billion by 2022 from USD 1.82 Billion in 2017, growing at a CAGR of 3.7%. The growth of this market is mainly driven by the growing geriatric population, increasing number of surgical procedures, and rising awareness programs globally.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206173813

Expansions accounted for the largest share of the overall growth strategies followed by key players between 2014 and 2017. Some of the companies that adopted this strategy include Medtronic (Ireland), B. Braun (Germany), Cardinal Health (US), Stryker (US), and Cook Medical (US).

The surgical drains market is highly competitive with several big and small players. Prominent players in this market include B. Braun (Germany), Cardinal Health (US), ConvaTec (UK), C.R. Bard (US), Redax (Italy), Ethicon (US), Stryker (US), Romsons (India), Medtronic (Ireland), Medline Industries (US), Cook Medical (US), Poly Medicure (India), Zimmer Biomet (Indiana), Global Medikit (India), Degania Silicone (Israel), Aspen Surgical (US), National Surgical (Australia), Axiom Medical (US), Péters Surgical (France), Ningbo Luke medical China), Goharshafa (Iran), ARMSTRONG MEDICAL (UK), Angiplast (India), CHIMED (Italy), and pfm medical (Germany).

B. Braun Melsungen held the leading position in the global surgical drains market in 2016. The company offers an extensive range of surgical drains. The company has a strong geographic presence and focuses on expansions to strengthen its foothold in the market. In September 2014, the company formed a new subsidiary—B. Braun of Canada, Ltd. This expansion enabled the company to work more closely with customers and Group Purchasing Organizations across the country. The company’s Hospital Care and Aesculap division witnessed a 4.7% and 3.7% growth in its net sales due to strong performance in surgical solutions in 2016. Aesculap also provides advanced training for physicians and specialists in hospitals and medical practices to enable them to keep up with the rapid pace of developments in the healthcare industry through the Aesculap Academy. The Aesculap Academy has local headquarters in more than 40 countries.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=206173813

Cardinal Health has a strong geographic presence and a robust product portfolio of surgical drains. As part of its growth strategy, Cardinal Health focuses on organic growth strategies like geographic expansions to increase and enhance its market presence in the surgical drains market. For instance, in 2015, the company opened its new healthcare supply chain innovation center in the US. It provides customized healthcare solutions to hospitals, ambulatory surgery centers, clinical laboratories, pharmacies, and physician offices across the globe. The company’s high-quality products and its presence across the globe help it to hold a leading position in the surgical drains market.

Ambulatory EHR Market Development | Industry Report 2021

According to research the research report Ambulatory EHR Market is expected to reach USD 5.20 billion by 2021 from USD 3.92 billion in 2016, at a CAGR of 5.8%. The Asia-Pacific region presents huge opportunities for growth in the ambulatory EHR market owing to the investments and reforms to modernize China’s healthcare infrastructure, the digital healthcare scenario in India, Japan’s favourable outlook for HCIT, and the implementation of e-Health in Australia.

Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=235617627

The report provides an overall understanding of the market. The application segment includes practice management, patient management, e-prescribing, referral management, population health management, decision support, and health analytics. In 2016, the practice management segment commanded the largest share of the global ambulatory EHR market. These solutions increase the efficiency of day-to-day operations, enhance the value of services provided, and ensure compliance with regulatory requirements.

The delivery mode segment of the market includes cloud-based solutions and on-premise solutions. The cloud-based solutions segment commanded the largest share of the global ambulatory EHR market in 2016 and is expected to be the fastest growing segment during the forecast period. The market is mainly driven by the advantages associated with cloud-based solutions, which include flexibility and cost reduction in healthcare delivery.

Based on practice size, the global ambulatory EHR market is categorized into large practices, small-to-medium-sized practices, and solo practices. The large practices segment commanded the largest share of the global ambulatory EHR market in 2016, owing to factors such as the availability of capital investments, ability to handle the productivity challenges that are created by new EHR adoption, and ability to choose among vendors. However, the small-to-medium-sized practices segment is estimated to register the highest growth rate primarily due to the funding provided by regional exchange centres (REC) to support the adoption of EHR among these users.

The end user segment of the ambulatory EHR market includes hospital-owned ambulatory centres and independent centres. The hospital-owned ambulatory centres segment commanded the largest share of the global ambulatory EHR market in 2016 and is expected to be the fastest growing segment during the forecast period. The large share and high growth rate of hospital-owned ambulatory centres can be attributed to the growing need to improve the profitability of healthcare operations and ensure cost-containment by preventing unnecessary healthcare spending, along with government initiatives to improve the quality of care and payment deduction for eligible professionals who are not meaningful users of Certified EHR.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=235617627

North America accounted for the largest share of the market in 2016. The large share of the North American ambulatory EHR market can be attributed to factors such as federal mandates, increasing geriatric population, collaboration between stakeholders, the need to curtail healthcare costs, payment deductions driving the adoption of EHR, conferences and workshops to raise awareness in the U.S., growing efforts to enhance healthcare delivery, and the adoption of digital recordkeeping in Canada.

Blood Gas Analyzer Market Recent Development | Industry Report 2021

According to research report the blood gas analyzer market was estimated to be USD 506.9 Million in 2016, which would reach USD 636 Million by 2021, growing at a CAGR of 4.6% during 2016 to 2021.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=242278963

The major players in the global blood gas analyzer market are Abbott Laboratories (U.S.), Alere, Inc. (U.S.), Instrumentation Laboratory (U.S.), Radiometer (Denmark), Roche Diagnostics (Switzerland), and Siemens Healthcare (Germany). The top 3 companies together account for a share of more than 70% of the global market. These players have adopted several strategies to remain competitive in this space. Enhancement of existing products, development of new products, collaborations and agreements are among the top strategies adopted by the leading companies in blood gas analyzers market.

Companies such as Roche Diagnostics Limited, Nova Biomedical, Abbott Laboratories, and OPTI Medical Systems, Inc. adopted the strategy of new product launch to develop novel blood gas analyzers, strengthen their product portfolios, and address the demands of their customers. In June 2016, Roche Diagnostics launched its blood gas learning application, namely, Blood Gas Learn Your ABGs. The new app helps in learning and interpreting arterial blood gases. This enabled the company to enhance its market visibility. Similarly, Nova launched Stat Profile Prime, a blood gas analyzer, in May 2014. This testing system can be combined with Nova’s zero maintenance cartridge technology, which gives faster and accurate results. The launch of this product helped the company to expand its product offerings in the point-of-care testing market.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=242278963

North America is estimated to dominate the global blood gas analyzer market in 2016. The large share of this regional segment can primarily be attributed to the growing prevalence of lifestyle diseases, increasing number of product approvals, and rising government initiatives. On the other hand, the Asia-Pacific market is expected to witness the highest growth during the forecast period, owing to factors such as growing initiatives by market players and increasing patient population base in this region.